Global Immunotherapy Expansion And AI Automation Will Reshape Long Term Prospects

Catalysts

About ImmunityBio

ImmunityBio is a commercial stage immunotherapy company focused on ANKTIVA and a broader platform of cytokine, cell therapy, and DNA vaccine candidates for oncology and immune related conditions.

What are the underlying business or industry changes driving this perspective?

• The rapid global expansion of ANKTIVA into 33 countries, including the U.S., EU, U.K., and Saudi Arabia, together with commercial partners like Accord and regional distributors, sets up a much larger treated patient base over time, which is directly tied to future product revenue growth.
• The broad use of checkpoint inhibitors across many tumor types has created a large pool of patients with limited options after checkpoint failure. ANKTIVA combinations targeting this setting, such as in QUILT-3.055, address an existing treatment gap that could influence future revenue and potentially support higher utilization per patient.
• The decade long shortage of BCG for bladder cancer and ImmunityBio’s recombinant BCG program, already serving hundreds of patients under expanded access, position the company to address a chronic supply issue in urology. This may widen its bladder cancer franchise and affect longer term revenue visibility.
• The recognition of lymphopenia as a widespread health issue, with JAMA citing about 52 million Americans affected, together with ANKTIVA’s FDA affirmed effect on NK and T cell counts, opens up a broad potential use case beyond oncology. If converted into approved indications, this could influence both top line growth and the durability of earnings.
• The integration of AI driven tools like askIB into R&D, manufacturing and commercial operations, along with the NANT Leonardo robotic cell manufacturing platform, is aimed at higher throughput and lower unit costs. This can support margin improvement as volumes scale and help narrow losses over time.

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming ImmunityBio's revenue will grow by 118.9% annually over the next 3 years.
• Analysts assume that profit margins will increase from -310.2% today to 36.7% in 3 years time.
• Analysts expect earnings to reach $435.5 million (and earnings per share of $0.44) by about March 2029, up from $-351.4 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $648.4 million in earnings, and the most bearish expecting $193.0 million.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 48.1x on those 2029 earnings, up from -29.3x today. This future PE is greater than the current PE for the US Biotechs industry at 21.8x.
• Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.2%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• ImmunityBio is investing heavily to build an expansive multi platform oncology and immunology franchise. If ongoing and planned trials in additional cancers, lymphopenia or prevention settings fail to show clear clinical benefit, the current concentration of revenue in ANKTIVA for bladder cancer could persist, which would limit long term revenue diversification and keep earnings reliant on a single core indication.
• The company is running numerous single arm and combination trials, while also leaning on concepts like the plausible mechanism of action pathway for potential approvals. If regulators apply stricter standards than anticipated or do not extend approvals beyond bladder and Saudi lung cancer, timelines for new indications may lengthen, which would pressure revenue growth, keep net margins under strain and delay the path to positive earnings.
• The business model assumes broad global adoption of ANKTIVA across 33 countries, expansion through partners like Accord, Biopharma and Cigalah, and eventual uptake of recombinant BCG and cell therapies. If payers, hospitals or physicians are slower to adopt these products or reimbursement terms are less favorable than hoped, unit volumes and net product revenue could fall short, which would limit operating leverage and keep net margins weak.
• Management is positioning ANKTIVA as a backbone for lower dose chemotherapy, radiation, BCG and checkpoint inhibitors, and as a possible answer to lymphopenia that affects tens of millions of people. If competitors in immunotherapy, cell therapy or cancer vaccines deliver better or cheaper options, ImmunityBio may face pricing pressure and share loss in key markets, which would weigh on revenue growth and may prevent the forecast improvement in profit margins and earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $13.5 for ImmunityBio based on their expectations of its future earnings growth, profit margins and other risk factors.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $23.0, and the most bearish reporting a price target of just $7.0.
  
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $1.2 billion, earnings will come to $435.5 million, and it would be trading on a PE ratio of 48.1x, assuming you use a discount rate of 7.2%.
  
• Given the current share price of $10.0, the analyst price target of $13.5 is 25.9% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.